A wave of landmark clinical research has dramatically expanded the potential reach of one of medicine's most promising kidney drugs. Three major studies published the week of June 5, 2026 — in the New England Journal of Medicine, JAMA, and The Lancet — have confirmed that finerenone, a mineralocorticoid receptor antagonist previously approved for chronic kidney disease (CKD) in patients with type 2 diabetes, also offers significant protection for patients with non-diabetic kidney disease — a far larger and previously undertreated population.
The findings were presented at the 2026 European Renal Association Congress in Glasgow and published simultaneously in the three journals, representing the most concentrated set of finerenone evidence ever released at one time.
